Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA.

5 Jan 2016

Children suffering from neuroblastoma may benefit from potential new treatment

Children suffering from a cancer of the nervous system could benefit from a potential new treatment, thanks to an international team led by researchers at the University of Kent and at the Institute of Medical Virology at the Goethe-University, Frankfurt am Main, Germany.

7 Dec 2015

Crucial change in single DNA base predisposes children to aggressive form of cancer

Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form.

12 Nov 2015

Environmental factors may lead to development of some childhood cancers

Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.

10 Nov 2015

International research project examines effectiveness of tried and tested medicines for different diseases

The Medical University of Vienna is coordinating an international research project, which investigates the effectiveness of tried and tested medicines for the treatment of some of the heaviest burdens of our modern society including diseases such as cancer, diabetes and cardiovascular diseases. One molecule that these disorders have in common is a receptor known as the calcium-sensing receptor (CaSR), which is the molecular starting point of this project.

4 Nov 2015

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells, found a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Postdoctoral fellow Brian Altman, PhD, and doctoral student Annie Hsieh, MD, both from the lab of senior author Chi Van Dang, MD, PhD, director Abramson Cancer Center, study body clock proteins associated with cancer cells.

18 Sep 2015

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

The Children's Hospital at Montefiore and the NCI-designated Albert Einstein Cancer Center today announced receipt of $1.3 million grant from the National Cancer Institute, part of the National Institutes of Health.

9 Sep 2015

AbbVie’s subsidiary to acquire United Therapeutics’ Rare Pediatric Disease Priority Review Voucher

United Therapeutics Corporation announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PPRV) to a subsidiary of AbbVie Inc.

19 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Childhood cancer cells produce molecule that affects body's immune system to fight disease

Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body's immune cells, leaving them too physically drained to fight the disease, according to new research published in the journal Cancer Research today (Saturday).

3 Aug 2015

UofL conducts Phase I research study for children with relapsed tumors

Zach feels "pretty good." Sam wants to be "done with shots!" And Tyler finds it helps to "just keep thinking that at least I'm getting out of school." They are normal boys who had normal lives until cancer came into the picture. All have faced the disease for two years or more, with surgeries, chemotherapy and radiation treatments. All were diagnosed with various malignant solid tumors, went into remission and then relapsed.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.

2 Jul 2015

Study may lead to better treatments for children with neuroblastoma

Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.

30 Jun 2015

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic.

24 Jun 2015

Dell extends partnership with TGen to globally expand precision medicine trial for pediatric cancer

Dell today announced its extended partnership with the Translational Genomics Research Institute to help clinical researchers and doctors globally expand the reach and impact of the world's first Food and Drug Administration-approved precision medicine trial for pediatric cancer.

11 Jun 2015

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."

2 Jun 2015

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

In a report on what is believed to be the first small clinical trial of its kind, researchers at the Johns Hopkins Kimmel Cancer Center say they have safely used immune cells grown from patients' own bone marrow to treat multiple myeloma, a cancer of white blood cells.

21 May 2015

Researchers make major step toward finding target to combat drug-resistant neuroblastoma

Researchers at Children's Hospital Los Angeles have made an important step toward finding a target in the fight against drug-resistant neuroblastoma (NBL), the most common solid malignancy found, outside of the skull, in children.

14 May 2015

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Children suffering from neuroblastoma may benefit from potential new treatment

Crucial change in single DNA base predisposes children to aggressive form of cancer

Environmental factors may lead to development of some childhood cancers

International research project examines effectiveness of tried and tested medicines for different diseases

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

AbbVie’s subsidiary to acquire United Therapeutics’ Rare Pediatric Disease Priority Review Voucher

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Childhood cancer cells produce molecule that affects body's immune system to fight disease

UofL conducts Phase I research study for children with relapsed tumors

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Study may lead to better treatments for children with neuroblastoma

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Dell extends partnership with TGen to globally expand precision medicine trial for pediatric cancer

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

Researchers make major step toward finding target to combat drug-resistant neuroblastoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in